| Title: |
Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. |
| Authors: |
Salanova, Vicenta; Salanova, Vicenta; Witt, Thomas; Worth, Robert; Henry, Thomas R; Gross, Robert E; Nazzaro, Jules M; Labar, Douglas; Sperling, Michael R; Sharan, Ashwini; Sandok, Evan; Handforth, Adrian; Stern, John M; Chung, Steve; Henderson, Jaimie M; French, Jacqueline; Baltuch, Gordon; Rosenfeld, William E; Garcia, Paul; Barbaro, Nicholas M; Fountain, Nathan B; Elias, W Jeffrey; Goodman, Robert R; Pollard, John R; Tröster, Alexander I; Irwin, Christopher P; Lambrecht, Kristin; Graves, Nina; Fisher, Robert; SANTE Study Group |
| Source: |
Neurology; vol 84, iss 10, 1017-1025; 0028-3878 |
| Publisher Information: |
eScholarship, University of California 2015-03-01 |
| Document Type: |
Electronic Resource |
| Abstract: |
ObjectiveTo report long-term efficacy and safety results of the SANTE trial investigating deep brain stimulation of the anterior nucleus of the thalamus (ANT) for treatment of localization-related epilepsy.MethodsThis long-term follow-up is a continuation of a previously reported trial of 5- vs 0-V ANT stimulation. Long-term follow-up began 13 months after device implantation with stimulation parameters adjusted at the investigators' discretion. Seizure frequency was determined using daily seizure diaries.ResultsThe median percent seizure reduction from baseline at 1 year was 41%, and 69% at 5 years. The responder rate (≥50% reduction in seizure frequency) at 1 year was 43%, and 68% at 5 years. In the 5 years of follow-up, 16% of subjects were seizure-free for at least 6 months. There were no reported unanticipated adverse device effects or symptomatic intracranial hemorrhages. The Liverpool Seizure Severity Scale and 31-item Quality of Life in Epilepsy measure showed statistically significant improvement over baseline by 1 year and at 5 years (p < 0.001).ConclusionLong-term follow-up of ANT deep brain stimulation showed sustained efficacy and safety in a treatment-resistant population.Classification of evidenceThis long-term follow-up provides Class IV evidence that for patients with drug-resistant partial epilepsy, anterior thalamic stimulation is associated with a 69% reduction in seizure frequency and a 34% serious device-related adverse event rate at 5 years. |
| Index Terms: |
SANTE Study Group; Anterior Thalamic Nuclei; Humans; Epilepsies; Partial; Treatment Outcome; Deep Brain Stimulation; Severity of Illness Index; Follow-Up Studies; Time Factors; Quality of Life; Adolescent; Adult; Aged; Middle Aged; Female; Male; Young Adult; Neurodegenerative; Neurosciences; Clinical Trials and Supportive Activities; Clinical Research; Epilepsy; Brain Disorders; Patient Safety; Neurological; Clinical Sciences; Cognitive Sciences; Neurology & Neurosurgery; article |
| URL: |
https://escholarship.org/uc/item/7px3f01g; https://escholarship.org/ |
| Availability: |
Open access content. Open access content; public |
| Note: |
application/pdf; Neurology vol 84, iss 10, 1017-1025 0028-3878 |
| Other Numbers: |
CDLER oai:escholarship.org:ark:/13030/qt7px3f01g; qt7px3f01g; https://escholarship.org/uc/item/7px3f01g; https://escholarship.org/; 1377969933 |
| Contributing Source: |
UC MASS DIGITIZATION; From OAIster®, provided by the OCLC Cooperative. |
| Accession Number: |
edsoai.on1377969933 |
| Database: |
OAIster |